Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Biotech
Pfizer CEO makes case for $6B bet on 'fabulous' bispecific
Albert Bourla pulled back the curtain on his PD-1xVEGF bispecific bet, revealing the lengths his team went to to gain reassurance about Chinese data.
Nick Paul Taylor
Jun 10, 2025 9:56am
To Gilead's new CMO, pipeline diversification is key
Jun 9, 2025 10:00am
BMS inks $11B biobucks BioNTech deal to join bispecific rush
Jun 2, 2025 8:59am
Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific
May 20, 2025 4:47am
GSK axes $625M TIGIT drug as midphase data disappoint
May 13, 2025 9:44am
Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3
Apr 28, 2025 7:25am
